Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Oropharyngeal candidiasis |
Dose: Intravenous Injection – 200 mg on the first day, followed by 100 mg Frequency: once daily Duration: at least 2 weeks Note: Treatment should be continued for at least 2 weeks to decrease the likelihood of relapse. |
|
Indication: Esophageal candidiasis |
Dose: Intravenous Injection – 200 mg on the first day, followed by 100 mg Frequency: once daily Duration: minimum of 3 weeks and for at least 2 weeks following resolution of symptoms Note: Doses up to 400 mg/day may be used, based on medical judgment of the patient’s response to therapy. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Oropharyngeal candidiasis Age: Children |
Dose: Intravenous – 6 mg/kg Frequency: once daily Duration: first day Note: Followed by 3 mg/kg once daily |
|
Indication: Oropharyngeal candidiasis Age: Children |
Dose: Intravenous – 3 mg/kg Frequency: once daily Duration: at least 2 weeks Note: Followed after 6 mg/kg on the first day to decrease the likelihood of relapse |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Haemodialysis |
Dose: Dosage Form – Usual dose Note: Dose given after each session |
|
Condition: Renal impairment with Creatinine Clearance less than 50 ml/min and not receiving dialysis |
Dose: Dosage Form – 50% of the usual dose |
Administration
- For hospital use only
- Must be administered by healthcare professionals
Side Effect
- Headache (2-13%)
- Nausea (2-7%)
- Abdominal pain (2-6%)
- Diarrhea (2-3%)
- Rash (2%)
- Vomiting (2-5%)
- QT prolongation
- Torsades de pointes
- Alopecia
- Anaphylactic reactions
- Angioedema
- Cholestasis
- Dizziness
- Dyspnea
- Hepatic failure
- Hepatitis
- Hypertriglyceridemia
- Hypokalemia
- Increased alkaline phosphatase
- Increased ALT/AST
- Jaundice
- Leukopenia
- Pallor
- Seizures
- Stevens-Johnson syndrome
- Taste perversion
- Thrombocytopenia
- Toxic epidermal necrolysis
- Hepatotoxicity
- rarely anaphylaxis
- Stevens-Johnson syndrome
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), Phenytoin, Theophylline, Tofacitinib, Rifabutin
|
May increase plasma concentrations
|
|
Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban)
|
May increase prothrombin time
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Known Hypersensitivity
|
Risk of severe allergic reaction
|
|
Advanced Liver Disease
|
Can worsen liver function
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.